Alphagan-P®
Brimonidine tartrate 0.1%, 0.15% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in open-angle glaucoma or ocular hypertension
1 drop in the affected eye(s) TID, approximately 8 hours apart
IOP control equals brimonidine 0.2% with 41% less allergic conjunctivitis over 12 months.
Elevated IOP in open-angle glaucoma or ocular hypertension, used concomitantly with other topical IOP-lowering drugs
one drop in the affected eye(s) three times daily, approximately 8 hours apart; instill at least 5 minutes apart from other topical ophthalmic products
Added to latanoprost, mean diurnal IOP fell from 19.6 to 16.3 mm Hg at 3 months.
OFF-LABELNot in the FDA label for this product
IOP spike prophylaxis for Nd:YAG posterior capsulotomy
1 drop 1 hour before the laser and 1 drop immediately after
RCT · n=106 · single-site
Prospective, double-masked, randomized trial, 106 eyes, comparing 0.15% Purite, 0.2%, and vehicle: both active arms fell 2.2 to 2.7 mm Hg below baseline while vehicle rose. Elevations under 5 mm Hg occurred in 27.8% of the 0.15% Purite arm, 22.9% of the 0.2% arm, and 48.6% of vehicle; spikes above 10 mm Hg in 2.8%, 2.9%, and 8.6%. Single-center, and the two strengths did not differ from each other.
Low-pressure (normal-tension) glaucoma, visual field preservation
Trial dose was brimonidine 0.2% BID, not the 0.1% or 0.15% strengths and not the labeled TID frequency
RCT · very low certainty
LoGTS randomized, double-masked, multicenter trial, 178 patients with untreated IOP 21 mm Hg or lower: field progression by pointwise linear regression in 9.1% on brimonidine 0.2% BID versus 39.2% on timolol 0.5% BID (p=0.001) at equivalent treated IOP, but 28.3% versus 11.4% withdrew for drug-related adverse events. A Cochrane review graded the finding very low certainty because 40.5% never completed 4 years and attrition was unbalanced (55% brimonidine versus 29% timolol), and concluded no reliable inference could be drawn.
Contraindications
- Neonates and infants younger than 2 years old
- Hypersensitivity reaction to any component of this medication in the past
0.1% (1 mg/mL) and 0.15% (1.5 mg/mL) Purite-preserved solution, 5 mL, 10 mL, and 15 mL bottles in each strength
Relatively selective alpha-2 adrenergic agonist. Fluorophotometric studies in animals and humans suggest a dual mechanism, reducing aqueous humor production and increasing uveoscleral outflow. Peak ocular hypotensive effect occurs about 2 hours after instillation.
Warnings & Precautions
- Infant CNS and respiratory depression: Apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants; contraindicated under 2 years.
- Vascular insufficiency: May potentiate syndromes associated with vascular insufficiency; caution in depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
- Severe cardiovascular disease: Minimal blood pressure effect in clinical studies, but caution in severe cardiovascular disease.
- Decreased mental alertness: ALPHAGAN P may cause fatigue and/or drowsiness in some patients. Caution patients who engage in hazardous activities of the potential for a decrease in mental alertness.
- Reduced blood pressure and additive or potentiating effects: Because ALPHAGAN P may reduce blood pressure, caution is advised with antihypertensives and/or cardiac glycosides. The possibility of an additive or potentiating effect with CNS depressants should be considered. MAO inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in increased hypotension. Caution is advised with tricyclic antidepressants and MAO inhibitors.
- Bacterial keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that patients had inadvertently contaminated. Do not touch the tip of the dispensing container to the eye or surrounding structures; serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
- Delayed-onset ocular allergy: In a private glaucoma practice cohort started on brimonidine, 36 of 140 patients (25.7%) had allergic contact dermatoconjunctivitis or follicular conjunctivitis, and the rate showed a fairly linear curve with no peak. Among patients previously allergic to apraclonidine, the five who reacted to brimonidine did so at 8.2+/-1.2 months, a small retrospective chart review that should not be read as a general time course.
Common Side Effects
Adverse reactions occurring in approximately 10% to 20% of subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Reactions in approximately 5% to 9% included burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. Reactions in approximately 1% to 4% included blepharitis, follicular conjunctivitis, keratitis, superficial punctate keratopathy, eye dryness, blurred vision, foreign body sensation, headache, somnolence, fatigue, dizziness, insomnia, hypotension, abnormal taste, and infection (primarily colds and respiratory infections). Postmarketing reports include bradycardia, tachycardia, syncope, depression, iritis, miosis, and keratoconjunctivitis sicca; it is not always possible to reliably estimate their frequency.
Pregnancy: No adequate and well-controlled studies in pregnant women and human data are insufficient; oral dosing in rabbits caused miscarriage at 5 mg/kg/day (about 50 to 70 times the ophthalmic dose by AUC) with no treatment-related malformations in rabbits or rats. Use during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
Lactation: Not recommended during lactation because of the potential for serious adverse reactions, including central nervous system depression and apnea, in nursing infants; human milk excretion unknown, present in rat milk.
Contraindicated under 2 years; use with caution in pediatric patients aged 2 years and older. On the 0.2% concentration TID, somnolence occurred in 50% to 83% at ages 2 to 6 and appears to occur less frequently (25%) at 7 years and older (greater than 20 kg); approximately 16% discontinued due to somnolence.